“…In the past decade there has been a growing concern among clinicians and researchers that use of AAPs may be related to potentially serious adverse metabolic effects, including weight gain, hyperlipidemia and glucose intolerance (Koller et al, 2001;Allison and Casey, 2001;Wirshing et al, 2002;Koller and Doraiswamy, 2002;Meyer, 2002;Jin et al, 2002;Koller et al, 2003;Koller et al, 2004;Jin et al, 2004;Meyer and Koro, 2004;Sathyaprakash and Henry, 2004;Newcomer, 2005). Clinical studies indicate that certain antipsychotics carry a high risk of treatment-related metabolic dysfunction (e.g.…”